{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0000315545","name":"PROVECTUS BIOPHARMACEUTICALS, INC.","summary":"Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines based on rose bengal sodium (RBS), a synthetic small molecule halogenated xanthene. Its drug candidates include intratumoral PV-10 for melanoma, liver cancer, penile SCC, and pancreatic cancer; topical PH-10 for psoriasis and atopic dermatitis; topical PV-305 for infectious keratitis; and oral PV-10 formulations for hematologic and solid tumor cancers.","people":[],"products":[{"name":"PV-10 (intratumoral)","type":"platform","description":"Rose bengal sodium formulation administered intratumorally for melanoma, liver cancer, penile SCC, and pancreatic cancer clinical trials."},{"name":"PH-10 (topical)","type":"platform","description":"Topical PV-10 formulation for treatment of psoriasis and atopic dermatitis in mid-stage clinical trials."},{"name":"PV-305 (topical ophthalmic)","type":"platform","description":"Topical RBS formulation for ocular diseases such as infectious keratitis, studied at Bascom Palmer Eye Institute."},{"name":"PV-10 (oral)","type":"platform","description":"Oral RBS formulation for non-clinical proof-of-concept study in solid tumor and hematologic cancers."},{"name":"RBS API","type":"platform","description":"Proprietary pharmaceutical-grade rose bengal sodium active pharmaceutical ingredient manufactured via patented synthesis process."}],"partnerships":[{"partner_name":"Moffitt Cancer Center","partnership_type":"development","description":"Clinical trial site for penile SCC and mPDAC PV-10 studies; mechanism of action research for melanoma.","start_date":null},{"partner_name":"The Rockefeller University","partnership_type":"development","description":"Clinical and non-clinical mechanism of action and immune response study for psoriasis using PH-10.","start_date":null},{"partner_name":"University of Miami / Bascom Palmer Eye Institute","partnership_type":"development","description":"Collaboration to evaluate pharmaceutical-grade RBS for infectious keratitis; co-founded VisiRose, Inc.","start_date":null},{"partner_name":"University of Calgary, Cumming School of Medicine","partnership_type":"development","description":"Non-clinical research on intratumoral and oral PV-10 for pediatric solid tumors, adult solid tumors, and blood cancers.","start_date":null},{"partner_name":"University of Texas Medical Branch","partnership_type":"development","description":"Non-clinical monotherapy study of topical PV-10 for full-thickness cutaneous wound healing.","start_date":null},{"partner_name":"University of Tennessee College of Veterinary Medicine","partnership_type":"development","description":"Non-clinical study of PV-10 for cutaneous canine cancers; intratumoral POC achieved.","start_date":null},{"partner_name":"University of Tennessee Health Science Center","partnership_type":"development","description":"Non-clinical study of PV-10 for bacterial, fungal, and infectious disease indications.","start_date":null},{"partner_name":"MD Anderson Cancer Center","partnership_type":"development","description":"Clinical study of PV-10 mechanisms of action and immune response for melanoma and metastatic tumors.","start_date":null},{"partner_name":"The Queen Elizabeth Hospital (Adelaide, Australia)","partnership_type":"development","description":"Clinical site for PV-10 mechanism of action studies including metastatic uveal melanoma.","start_date":null},{"partner_name":"University of Nevada, Las Vegas","partnership_type":"development","description":"Non-clinical study of PV-10 formulations for vertebrate development, wound healing, and tissue regrowth.","start_date":null}],"affiliations":[],"origin":{"leaf":"a814a11b4027effc254d101d530610fd6598238d7ad6190e882bb834c4e88180","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"754dee239bb8e1562993816109687486f3d29979dc1fac802c092b122c9e3498","parent":"edf8107200d3d2acd2f8bad9ae942e6e6d44ca56e1e98a460d34de32cd53f867","source":"0001493152-26-012726","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":14,"hourly_limit":500,"remaining":486,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}